Gogo partnering on installs with European air group
May 5 2016, 16:00 ET | By: Jason Aycock, SA News Editor
Gogo (GOGO +1.5%) is partnering with International Airlines Group in order to bring its 2Ku in-flight technology to dozens more aircraft.
It's the first European airline group to commit to Gogo's next-gen solution.
The company will deploy 2Ku on 118 aircraft at British Airways, four Boeing 757s at Aer Lingus (OTC:AIRXY) and up to 15 long-haul craft at Iberia.
Most installations are set to be completed by 2019; the first British Airways craft is set for service early next year.
Geron Corporation Reports First Quarter 2016 Financial Results and Recent Events
Thu May 5, 2016 4:05 PM|GlobeNewswire | About: GERN
MENLO PARK, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) today reported financial results for the first quarter ended March 31, 2016 and recent events.
First Quarter 2016 Results
For the first quarter of 2016, the company reported operating revenues of $749,000 and operating expenses of $9.8 million compared to $537,000 and $10.0 million, respectively, for the comparable 2015 period. Revenues for the first quarter of 2016 and 2015 included royalty and license fee revenues under various non-imetelstat agreements. Operating expenses in the first quarter of 2015 included restructuring charges of $406,000 in connection with the company’s organizational resizing announced in March 2015. Net loss for the first quarter of 2016 was $8.8 million, or $0.06 per share, compared to $9.3 million, or $0.06 per share, for the comparable 2015 period. The company ended the first quarter of 2016 with $141.9 million in cash and investments.
Research and development expenses for the first quarter of 2016 and 2015 were $5.0 million for each period. Research and development expenses for 2016 primarily reflect the net result of higher costs for the company’s proportionate share of clinical development expenses under the imetelstat collaboration with Janssen Biotech, Inc. (Janssen), partially offset by lower personnel related expenses as a result of the 2015 organizational resizing. The company expects research and development expenses to increase during the remainder of the year as the clinical development of imetelstat continues in collaboration with Janssen.
General and administrative expenses for the first quarter of 2016 were $4.8 million compared to $4.6 million for the comparable 2015 period. The increase in general and administrative expenses primarily reflects the net result of higher non-c
Gogo (NASDAQ:GOGO) -- down as much as 6.5% today after it was brought up as a short idea at the Ira Sohn conference -- jumped in recent minutes back into positive ground on news that Delta Air Lines (NYSE:DAL) is adding Gogo's offering to at least 350 aircraft.
That brings Delta's commitment to Gogo's 2Ku in-flight Wi-Fi tech to more than 600 mainline aircraft.
The installation will offer Delta's customers bandwidth more than 20 times Gogo's ATG technology, Delta says, making for easier video streaming.
Now read Gogo And Airbus Strike A Deal »
By Arpita Dutt
May 3, 2016 9:20 AM
Geron Corporation GERN is scheduled to report first quarter 2016 results on May 5 after the market closes. The company’s fourth quarter 2015 loss was in-line with expectations. Let’s see how things are shaping up for the first quarter announcement.
Focus Remains on Imetelstat
With Geron being a development stage company, investor focus will remain on the company’s pipeline progress. Geron currently has one candidate in its pipeline, imetelstat, which is being developed in collaboration with Johnson & Johnson’s JNJ Janssen Biotech.
Imetelstat is currently in a phase II study (IMbark) in patients with DIPSS intermediate-2 or high-risk myelofibrosis who have relapsed after or are refractory to a JAK inhibitor. An internal review to determine the adequacy of one or both of the initial dosing arms is slated for the second half of the year. Based on this review, a decision will be taken regarding the continuation/halting/modification of the dosing arms or the selection of alternative doses.
Imetelstat is in a phase II/III study as well for myelodysplastic syndrome (MDS). An internal review of this study (to support advancement into Part 2) is also expected in the second half of the year.
On the fourth quarter call, Geron had guided towards cash operating expenses of approximately $34 million in 2016 – this includes $18 million representing Geron’s share of cost for the studies under the Janssen collaboration, about $9 million in personnel related cost, and $7 million for corporate costs like business development, legal, accounting, IT and facilities.
In addition to updates on imetelstat, investors will also be interested to know if Geron has made any progress in expanding its pipeline. The company is seeking to add new oncology candidates, programs or companies to its portfolio with its focus primarily on the hematology-oncology space.
Gern on sale continues. The elevator is going down. Many are predicting a USA recession by end of year.
Will take great news to buck the overall trend and most likely this "new" is not coming for 12 to 24 months. What say you?
Maineman, ...due to a recent financial set-back? How about a 15 year financial set back from Gern?
No need for an SOS I'm told help is coming, 6 to 18 months out, should I believe it old wise one?